Yoneda T - Search Results

1

Lower urinary tract symptoms after radical perineal prostatectomy.

Matsubara A, Yoneda T, Yasumoto H, Teishima J, Shiina H, Igawa M, Mita K, Usui T. Matsubara A, et al. Among authors: yoneda t. Jpn J Clin Oncol. 2007 Jul;37(7):534-9. doi: 10.1093/jjco/hym058. Epub 2007 Jul 24. Jpn J Clin Oncol. 2007. PMID: 17652108

2

Postoperative morbidity, functional results and quality of life of patients following orthotopic neobladder reconstruction.

Yoneda T, Igawa M, Shiina H, Shigeno K, Urakami S. Yoneda T, et al. Int J Urol. 2003 Mar;10(3):119-25. doi: 10.1046/j.1442-2042.2003.00591.x. Int J Urol. 2003. PMID: 12622705 Free article.

3

Blockade of paclitaxel-induced thymidine phosphorylase expression can accelerate apoptosis in human prostate cancer cells.

Kikuno N, Moriyama-Gonda N, Yoshino T, Yoneda T, Urakami S, Terashima M, Yoshida M, Kishi H, Shigeno K, Shiina H, Igawa M. Kikuno N, et al. Among authors: yoneda t. Cancer Res. 2004 Oct 15;64(20):7526-32. doi: 10.1158/0008-5472.CAN-04-0996. Cancer Res. 2004. PMID: 15492279

4

Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer.

Shiina H, Breault JE, Basset WW, Enokida H, Urakami S, Li LC, Okino ST, Deguchi M, Kaneuchi M, Terashima M, Yoneda T, Shigeno K, Carroll PR, Igawa M, Dahiya R. Shiina H, et al. Among authors: yoneda t. Cancer Res. 2005 Mar 15;65(6):2130-8. doi: 10.1158/0008-5472.CAN-04-3398. Cancer Res. 2005. PMID: 15781623

5

Yoneda T, Adachi H, Urakami S, Kishi H, Shigeno K, Shiina H, Igawa M. Yoneda T, et al. J Urol. 2005 Nov;174(5):1944-7. doi: 10.1097/01.ju.0000176455.82079.33. J Urol. 2005. PMID: 16217363

6

Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway.

Urakami S, Shiina H, Enokida H, Kawakami T, Tokizane T, Ogishima T, Tanaka Y, Li LC, Ribeiro-Filho LA, Terashima M, Kikuno N, Adachi H, Yoneda T, Kishi H, Shigeno K, Konety BR, Igawa M, Dahiya R. Urakami S, et al. Among authors: yoneda t. Clin Cancer Res. 2006 Jan 15;12(2):383-91. doi: 10.1158/1078-0432.CCR-05-1344. Clin Cancer Res. 2006. PMID: 16428476

7

Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy.

Yoshino T, Shiina H, Urakami S, Kikuno N, Yoneda T, Shigeno K, Igawa M. Yoshino T, et al. Among authors: yoneda t. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6116-24. doi: 10.1158/1078-0432.CCR-06-0147. Clin Cancer Res. 2006. PMID: 17062688

8

Usefulness of an immunochromatographical assay, PSA Rapid Test as a primary screening test for prostate cancer.

Shigeno K, Arichi N, Yoneda T, Kishi H, Shiina H, Igawa M. Shigeno K, et al. Among authors: yoneda t. Int Urol Nephrol. 2006;38(3-4):565-9. doi: 10.1007/s11255-006-0086-2. Epub 2006 Nov 16. Int Urol Nephrol. 2006. PMID: 17111081

9

Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer.

Kikuno N, Urakami S, Nakamura S, Hiraoka T, Hyuga T, Arichi N, Wake K, Sumura M, Yoneda T, Kishi H, Shigeno K, Shiina H, Igawa M. Kikuno N, et al. Among authors: yoneda t. Eur Urol. 2007 May;51(5):1252-8. doi: 10.1016/j.eururo.2006.12.030. Epub 2006 Dec 26. Eur Urol. 2007. PMID: 17208356 Clinical Trial.

10

Initial evaluation of prostate cancer with real-time elastography based on step-section pathologic analysis after radical prostatectomy: a preliminary study.

Sumura M, Shigeno K, Hyuga T, Yoneda T, Shiina H, Igawa M. Sumura M, et al. Among authors: yoneda t. Int J Urol. 2007 Sep;14(9):811-6. doi: 10.1111/j.1442-2042.2007.01829.x. Int J Urol. 2007. PMID: 17760747

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,016 results

Search Page

Filters